PURPOSE: To test whether a direct antiangiogenic peptide (anginex) and a vascular endothelial growth factor antibody (bevacizumab, Avastin) can transiently normalize vasculature within tumors to improve oxygen delivery, alleviate hypoxia, and increase the effect of radiation therapy. EXPERIMENTAL DESIGN: Tumor oxygenation levels, microvessel density and pericyte coverage were monitored in three different solid tumor models (xenograft human ovarian carcinoma MA148, murine melanoma B16F10, and murine breast carcinoma SCK) in mice. Multiple treatment schedules were tested in these models to assess the influence on the effect of radiation therapy. RESULTS: In all three tumor models, we found that tumor oxygenation levels, monitored daily in real time, were increased during the first 4 days of treatment with both anginex and bevacizumab. From treatment day 5 onward, tumor oxygenation in treated mice decreased significantly to below that in control mice. This "tumor oxygenation window" occurred in all three tumor models varying in origin and growth rate. Moreover, during the treatment period, tumor microvessel density decreased and pericyte coverage of vessels increased, supporting the idea of vessel normalization. We also found that the transient modulation of tumor physiology caused by either antiangiogenic therapy improved the effect of radiation treatment. Tumor growth delay was enhanced when single dose or fractionated radiotherapy was initiated within the tumor oxygenation window as compared with other treatment schedules. CONCLUSIONS: The results are of immediate translational importance because the clinical benefits of bevacizumab therapy might be increased by more precise treatment scheduling to ensure radiation is given during periods of peak radiosensitivity. The oxygen elevation in tumors by non-growth factor-mediated peptide anginex suggests that vessel normalization might be a general phenomenon of agents directed at disrupting the tumor vasculature by a variety of mechanisms.
PURPOSE: To test whether a direct antiangiogenic peptide (anginex) and a vascular endothelial growth factor antibody (bevacizumab, Avastin) can transiently normalize vasculature within tumors to improve oxygen delivery, alleviate hypoxia, and increase the effect of radiation therapy. EXPERIMENTAL DESIGN:Tumor oxygenation levels, microvessel density and pericyte coverage were monitored in three different solid tumor models (xenograft human ovarian carcinoma MA148, murinemelanoma B16F10, and murinebreast carcinoma SCK) in mice. Multiple treatment schedules were tested in these models to assess the influence on the effect of radiation therapy. RESULTS: In all three tumor models, we found that tumor oxygenation levels, monitored daily in real time, were increased during the first 4 days of treatment with both anginex and bevacizumab. From treatment day 5 onward, tumor oxygenation in treated mice decreased significantly to below that in control mice. This "tumor oxygenation window" occurred in all three tumor models varying in origin and growth rate. Moreover, during the treatment period, tumor microvessel density decreased and pericyte coverage of vessels increased, supporting the idea of vessel normalization. We also found that the transient modulation of tumor physiology caused by either antiangiogenic therapy improved the effect of radiation treatment. Tumor growth delay was enhanced when single dose or fractionated radiotherapy was initiated within the tumor oxygenation window as compared with other treatment schedules. CONCLUSIONS: The results are of immediate translational importance because the clinical benefits of bevacizumab therapy might be increased by more precise treatment scheduling to ensure radiation is given during periods of peak radiosensitivity. The oxygen elevation in tumors by non-growth factor-mediated peptide anginex suggests that vessel normalization might be a general phenomenon of agents directed at disrupting the tumor vasculature by a variety of mechanisms.
Authors: Robert J Griffin; Brent W Williams; Robert Wild; Julie M Cherrington; Heonjoo Park; Chang W Song Journal: Cancer Res Date: 2002-03-15 Impact factor: 12.701
Authors: L G Presta; H Chen; S J O'Connor; V Chisholm; Y G Meng; L Krummen; M Winkler; N Ferrara Journal: Cancer Res Date: 1997-10-15 Impact factor: 12.701
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Ruud P M Dings; Yumi Yokoyama; Sundaram Ramakrishnan; Arjan W Griffioen; Kevin H Mayo Journal: Cancer Res Date: 2003-01-15 Impact factor: 12.701
Authors: Jeanne M du Manoir; Giulio Francia; Shan Man; Miriam Mossoba; Jeffrey A Medin; Alicia Viloria-Petit; Daniel J Hicklin; Urban Emmenegger; Robert S Kerbel Journal: Clin Cancer Res Date: 2006-02-01 Impact factor: 12.531
Authors: Christopher G Willett; Yves Boucher; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Ricky T Tong; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Sergey V Kozin; Mari Mino; Kenneth S Cohen; David T Scadden; Alan C Hartford; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Helen X Chen; Paul C Shellito; Gregory Y Lauwers; Rakesh K Jain Journal: Nat Med Date: 2004-01-25 Impact factor: 53.440
Authors: Amir Abdollahi; Kenneth E Lipson; Axel Sckell; Heike Zieher; Frank Klenke; Daniel Poerschke; Alexandra Roth; Xiaohong Han; Martin Krix; Marc Bischof; Philip Hahnfeldt; Hermann-Josef Grone; Juergen Debus; Lynn Hlatky; Peter E Huber Journal: Cancer Res Date: 2003-12-15 Impact factor: 12.701
Authors: C Hess; V Vuong; I Hegyi; O Riesterer; J Wood; D Fabbro; C Glanzmann; S Bodis; M Pruschy Journal: Br J Cancer Date: 2001-12-14 Impact factor: 7.640
Authors: Sunil Sharma; Ganesh Narayanasamy; Beata Przybyla; Jessica Webber; Marjan Boerma; Richard Clarkson; Eduardo G Moros; Peter M Corry; Robert J Griffin Journal: Technol Cancer Res Treat Date: 2016-07-08
Authors: Chang W Song; Yoon-Jin Lee; Robert J Griffin; Inhwan Park; Nathan A Koonce; Susanta Hui; Mi-Sook Kim; Kathryn E Dusenbery; Paul W Sperduto; L Chinsoo Cho Journal: Int J Radiat Oncol Biol Phys Date: 2015-05-16 Impact factor: 7.038
Authors: Mackenzie C McGee; J Blair Hamner; Regan F Williams; Shannon F Rosati; Thomas L Sims; Catherine Y Ng; M Waleed Gaber; Christopher Calabrese; Jianrong Wu; Amit C Nathwani; Christopher Duntsch; Thomas E Merchant; Andrew M Davidoff Journal: Int J Radiat Oncol Biol Phys Date: 2010-04 Impact factor: 7.038
Authors: Yunzhou Shi; Jason Oeh; Jeffrey Eastham-Anderson; Sharon Yee; David Finkle; Franklin V Peale; Jed Ross; Maj Hedehus; Nicholas van Bruggen; Rayna Venook; Sarajane Ross; Deepak Sampath; Richard A D Carano Journal: Neoplasia Date: 2013-11 Impact factor: 5.715
Authors: Chad R Haney; Adrian D Parasca; Xiaobing Fan; Rebecca M Bell; Marta A Zamora; Gregory S Karczmar; Helena J Mauceri; Howard J Halpern; Ralph R Weichselbaum; Charles A Pelizzari Journal: Magn Reson Med Date: 2009-08 Impact factor: 4.668